Table 2

Incidence rates of atrioventricular block, atrial fibrillation, pacemaker implantation and aortic regurgitation in patients with AS, uSpA, PsA and in GP comparators

ASuSpAPsAGP
Atrioventricular block II–III
 Subjects at risk, n6392516816 015265 725
 Incident events, n (male/female)31 (28/3)17 (15/2)55 (35/20)936 (616/320)
 Person-years at risk, n35 99527 77191 6641 771 585
 Overall incidence rates
  Crude rates0.9 (0.6 to 1.2)0.6 (0.3 to 0.9)0.6 (0.4 to 0.8)0.5 (0.5 to 0.6)
  Standardised rates*0.9 (0.6 to 1.3)1.2 (0.5 to 1.9)0.7 (0.5 to 0.9)
 Male incidence rates
  Crude rates1.1 (0.7 to 1.6)1.2 (0.6 to 1.9)0.9 (0.6 to 1.1)0.7 (0.7 to 0.8)
  Standardised rates†1.6 (0.9 to 2.2)1.8 (0.8 to 2.8)1.0 (0.6 to 1.3)
 Female incidence rates
  Crude rates0.3 (0 to 0.6)0.1 (0 to 0.3)0.4 (0.2 to 0.6)0.4 (0.3 to 0.4)
  Standardised rates†0.4 (0 to 0.8)0.6 (0 to 1.6)0.4 (0.2 to 0.6)
Atrial fibrillation
  Subjects at risk, n6184510315 550259 005
  Incident events, n (male/female)174 (132/42)77 (40/37)560 (281/279)9484 (5638/3846)
  Person-years at risk, n34 59227 29987 9671 711 828
 Overall incidence rates
  Crude rates5.0 (4.3 to 5.8)2.8 (2.2 to 3.5)6.4 (5.8 to 6.9)5.5 (5.4 to 5.7)
  Standardised rates*7.1 (5.6 to 8.6)6.4 (4.6 to 8.3)7.4 (6.7 to 8.0)
 Male incidence rates
  Crude rates5.6 (4.7 to 6.6)3.4 (2.3 to 4.4)7.2 (6.4 to 8.1)6.8 (6.6 to 7.0)
  Standardised rates†7.2 (5.8 to 8.5)7.1 (4.3 to 9.9)8.5 (7.4 to 9.5)
 Female incidence rates
  Crude rates3.8 (2.6 to 4.9)2.4 (1.6 to 3.2)5.7 (5.0 to 6.4)4.4 (4.2 to 4.5)
  Standardised rates†7.1 (4.5 to 9.7)5.8 (3.2 to 8.4)6.3 (5.5 to 7.1)
Pacemaker implantation
  Subjects at risk, n6382516215 990265 214
  Incident events, n (male/female)53 (39/14)21 (18/3)113 (58/55)1776 (1109/667)
  Person-years at risk, n35 88727 73291 3641 766 293
 Overall incidence rates
  Crude rates1.5 (1.1 to 1.9)0.8 (0.4 to 1.1)1.2 (1.0 to 1.5)1.0 (1.0 to 1.1)
  Standardised rates*2.0 (1.3 to 2.7)1.5 (0.7 to 2.2)1.5 (1.2 to 1.8)
 Male incidence rates
  Crude rates1.6 (1.1 to 2.1)1.5 (0.8 to 2.2)1.4 (1.1 to 1.8)1.3 (1.2 to 1.4)
  Standardised rates†2.1 (1.4 to 2.9)2.6 (1.1 to 4.1)1.7 (1.3 to 2.2)
 Female incidence rates
  Crude rates1.2 (0.6 to 1.9)0.2 (0.0 to 0.4)1.1 (0.8 to 1.4)0.7 (0.7 to 0.8)
  Standardised rates†1.9 (0.7 to 3.1)0.4 (0 to 0.8)1.3 (0.9 to 1.6)
Aortic regurgitation
  Subjects at risk, n6375517016 001265 759
  Incident events, n (male/female)24 (20/4)13 (7/6)62 (28/34)744 (453/291)
  Person-years at risk, n35 92727 78791 5311 771 918
 Overall incidence rates
  Crude rates0.7 (0.4 to 0.9)0.5 (0.2 to 0.7)0.7 (0.5 to 0.8)0.4 (0.4 to 0.5)
  Standardised rates*0.7 (0.4 to 1.1)0.7 (0.3 to 1.1)0.7 (0.5 to 0.9)
 Male incidence rates
  Crude rates0.8 (0.5 to 1.2)0.6 (0.1 to 1.0)0.7 (0.4 to 0.9)0.5 (0.5 to 0.6)
  Standardised rates†1.0 (0.6 to 1.5)0.9 (0.2 to 1.7)0.7 (0.5 to 1.0)
 Female incidence rates
  Crude rates0.3 (0.0 to 0.7)0.4 (0.1 to 0.7)0.7 (0.4 to 0.9)0.3 (0.3 to 0.4)
  Standardised rates†0.5 (0.0 to 0.9)0.5 (0.0 to 0.9)0.7 (0.5 to 1.0)
  • Rates are presented as number of events per 1000 person-years at risk. All rates are calculated with 95% CI given in parentheses.

  • *Age-adjusted and sex-adjusted with the GP cohort as reference.

  • †Age-adjusted with the GP cohort as reference.

  • AS, ankylosing spondylitis; GP, general population; PsA, psoriatic arthritis; uSpA, undifferentiated spondyloarthritis.